期刊文献+

干扰素-α治疗慢性乙型肝炎的疗效及其影响因素的研究(英文) 被引量:1

Study of Therapeutic Efficiency and Efficient Factor of Interferon for Chronic Hepatitis B
原文传递
导出
摘要 目的:分析影响干扰素-α(IFN-α)治疗慢性乙型肝炎(CHB)疗效的因素。方法:选择2006年到2009年青岛市传染病医院住院的CHB患者46例,应用IFN-α治疗48周,根据IFN-α治疗的疗效将其分为应答组与无应答组,评价患者的宿主、病毒载量及生化指标等因素对疗效的影响。结果:两组间的性别比例、年龄和病程无显著差异(P>0.05),应答组治疗前HBV-DNA载量低于无应答组,ALT水平高于无应答组,HBeAg阳性患者的应答率高于HBeAg阴性患者,差异均具有统计学意义(P<0.05),应答组在治疗12周时HBV-DNA载量下降>2log的比例高于无应答组,差异具有统计学意义(P<0.05)。结论:治疗前HBVDNA载量低、ALT水平高和HBeAg阳性以及治疗12周时的HBVDNA应答可以作为干扰素-α治疗慢性乙型肝炎48周时应答的预测因素。 Objective: To investigate the influencing factors of the efficacy of interferon α (IFN-α) on patients with chronic hep- atitis B (CHB). Methods: 46 cases of CHB patients were chosen in this study, who were treated with IFN-α for 48 weeks in Qingdao Hospital for Infectious Diseases from January 2006 to June 2009, which were divided into responding group and non-responding group according to the efficacy of IFN-α. The influence of host factors, viral loads and biochemical factors on the efficacy of IFN-α was de- tected. Results: The proportions of sex and the mean ages and courses of disease were similar in the two groups (P 0.05). The pre-treat- ment HBV-DNA loads were lower and the ALT levels were higher in responding group than those in non-responding group (P 0.05), while the responding rate of the patients with HBeAg positive was higher than that with HBeAg negative (P 0.05). The rate of HBV-DNA load decreased more than that of 2 log at the 12 weeks of treatment was significantly higher in the responding group than that in the non-responding group (P 0.05). Conclusion: The lower HBV DNA load, higher ALT level and HBeAg positive before treatment and the response of HBV DNA at the week 12 of treatment may be the predicting factors of the response at week 48 of IFN-α treatment in the CHB patients.
机构地区 青岛大学医学院
出处 《现代生物医学进展》 CAS 2011年第9期1741-1743,共3页 Progress in Modern Biomedicine
关键词 慢性肝炎 乙型 干扰素-Α 治疗 影响因素 Chronic hepatitis B Efficiency Interferon-α Influencing factors
  • 相关文献

参考文献18

  • 1Lee WM. Hepatitis B virus infection [J]. N Eegl J Med, 1997, 337(24): 1733-1745.
  • 2European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: mangement of chronic hepatitis B [J]. J Hepatol, 2009, 50:227-247.
  • 3Chinese Medical Institute of Infectious and Parasitic Liver Diseases Branch and the Branch [J]. Viral hepatitis prevention and treatment programs[J]. Journal of Hepatology, 2000,8 (6) :324-329.
  • 4Clinical application experts of lamivudine, expert consensus of lamivudine clinical application in2004 [J]. Journal of Hepatology, 2004,12(7):425-426.
  • 5Li Shunliang, Yang Weijun, Ren Ximin. Study of recombinant a-2b in- terferon treatment of chronic hepatitis B [J]. Chinese drugs and clinical, 2002,2(3):184-185.
  • 6Perrillo R. Benefits and risks of interferon therapy for hepatitis B [J]. Hepaology, 2009, 49(5 Suppl): 103-111.
  • 7Samuel CE. Antiviral actions of interferon [J]. Clin Mierobiol Rev, 2001, 14(4):778-809.
  • 8Liang S, Wei H, Sun R, et al. IFN alpha regulates NK cell eytotoxicity through STAT1 pathway [J]. Cytokine, 2003, 23(6): 190-199.
  • 9Sun Baoxia, Zhao Xinping. Clinical observation of 63 chronic hepatitis B patients treated with interferon a-2b [J]. 2000,40(12):36.
  • 10Wang Shiqian. Clinical observation of 62 chronic hepatitis B patients treated with interferona 1 b combined oxymatrine injeetion [J]. Xinxi- ang Medical Journals, 2004,21 (4):272-273.

同被引文献20

  • 1Cicek IE, Cicek E, Kayhan F, et al. The roles of BDNF, S100B, and oxidative stress in interferon-induced depression and the effect of an- tidepressant treatment in patients with chronic viral hepatitis: a prospective study[J]. J Psychosom Res, 2014, 76(3): 227-232.
  • 2Martin CS, Ionescu LN, Barbu CG, et al. Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon- alpha and ribavirin for chronic hepatitis C [J]. BMC Endocr Disord, 2014, 14(1): 10.
  • 3Kokordelis P, Kramar B, K/Jmer C, et al, An effective interferon-gam- ma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficivncy virus-positive patients[J]. Hepatology, 2014, 59(3): 814-827.
  • 4Larrubia JR, Lokhande MU, Moreno-Cubero E, et al. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-c 2b/ribavirin correlates with infection resolution[J]. Cell Immunol, 2013, 286(1-2): 31-38.
  • 5Chcn AY, Zcremski M, Chauhan R, et al. Persistence of hepatitis C virus during and alter otherwise clinically successful treatment of chronic hepatitis C with standard pcgylated interferon ct-2b and rib- avirin therapy[J]. PLoS One, 2013, 8(11): 80078.
  • 6Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C geno-type 1 patients[J]. J Hepatol, 2014, 60(3): 530-537.
  • 7Stattermayer AF, Strassl R, Maieron A, et al. Polymorphisms of inter- feron-h 4 and IL28B - effects on treatment response to interferon/rib- avirin in patients with chronic hepatitis C [J]. Aliment Pharmacol Ther, 2014, 39(1): 104-111.
  • 8Hou XJ, Xu JH, Wang J, et al. Can antidepressants prevent pegylated interferon-edribavidn-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-con- trolled trials?[J]. PLoS One, 2013, 8(10): e76799.
  • 9Narita Y, Genda T, Tsuzura H, et al. Prediction of liver stiffiaess hep- atocellular carcinoma in chronic hepatitis C patients on interfer-on-based anti-viral therapy [J]. J Gastroenterol Hepatol, 2014, 29(1): 137-143.
  • 10Minelli R, Spagnoli F, Marchesi E, et al. Course of graves disease in interferon-treated patients with chronic hepatitis C virus infection and in uninfected patients[J]. J Investig Med, 2013, 61 (8): 1173 - 1177.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部